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ABSTRACT 
Chronic lithium (Li) administration causes a nephrogenic 
diabetes insipidus and is associated with renal morphologic changes 
in both humans and experimental animals. The diuretic amiloride 
(Ami) is known to block the effect of lithium to inhibit the action 
of ADH in the toad urinary bladder. To characterize chronic Li- 
induced changes in water metabolism and renal morphology, and to 
investigate the effect of Ami on these changes, Sprague-Dawley rats 
were administered Li or Li and Ami in their food. Control groups 
included rats on a normal diet and rats made polyuric by allowing 
free access to a glucose solution. All rats were given access co 
a 0.46 M NaCl solution to prevent extracellular volume contraction. 
Urine osmolality both before and after DDAVP administration, total 
fluid intake, urine flow rate, plasma Li concentration, creatinine 
clearance, and hematocrit were monitored. Following 8 weeks of 
study renal tissue was examined by light and electron microscopy. 
After Day 6, Li/Ami rats in comparison to Li rats had reduced 
fluid intake, reduced urine flow (0.99-0.8 ml/h/lOOg BW vs 2.57-0.55, 
p <.02) and increased (546-58 mOsm/kg vs 229^42, p <.005) 
despite comparable plasma Li (0.74-0.07 mEq/L vs 0.71-0.13). 
+ + 
Creatinine clearance (1.3-0.2 ml/min vs 1.4-0.1), Hct and body wt 
were not different between Li / Ami and Li rats. This antidiuretic 
ir 
effect of Ami persisted for the 8 weeks of study. To determine 
if this effect of Ami was dependent on ADH, identical studies were 
performed in ADH-deficient Brattleboro (BB) rats. In comparison 
to Li-treated BB rats, Li / Ami BB rats had comparable water intake 
(113-9 ml/d/1OOg bw vs 96-4) urine flow (3.92-ml/h/100g bw vs 
3.22-0.16) and no difference in U (188-18 mOsm/kg vs 164^17). 
Osm 
Following DDAVP, water intake was reduced in Li / Ami BB rats but 
not in Li BB rats. 
In contrast to its marked effect on Li-induced polyuria, Ami 
did not reduce Li associated changes in renal morphology. By semi- 
quantitative scoring of interstitial inflammation (scale 0-4+) on 
light microscopy, only modest changes were observed in all groups. 
There was no significant difference in the severity of morphologic 
changes between Li and Li/Ami rats (1.2^0.4 vs 2.1^0.6). Li- 
treated rats did not have a significantly greater mean score than 
“1“ "i" . • 
controls (1.2-0.4 vs 0.7-0.3), but there was a significant difference 
in mean scores between Li/Ami rats and controls (2.1-0.6 vs 0.7^0.3, 
p <«05). These modest changes could be due, in part, to an effect 
of polyuria per se since significantly higher scores were observed 
in glucose drinking polyuric rats in comparison to controls (2.1-0.4 
vs 0.7-0.3, p<. 01). 
By electron microscopy, a striking and previously unreported 
lesion was associated with Li administration. Cytoplasmic bundles 
. 
of microfilaments were observed in the light cells of the collect¬ 
ing duct in all 7 Li or Li/Ami rats, but in none of the 6 rats 
that did not receive Li. 
These studies demonstrate that amiloride specifically blocks 
the effect of Li on the renal tubular response to ADH, but that 
amiloride has no apparent effect on Li associated morphologic 
change. In addition, Li administration was associated with a marked 
aggregation of cytoplasmic fibrils. This change in the cellular 
cytoskeleton could be involved in the effeces of Li on the cellular 
action of ADH. 

INTRODUCTION 
1. Purpose 
In 1949, Cade first reported the beneficial effect of lithium 
(Li) on manic patients (21). Subsequent studies have established 
Li as an effective agent in the prevention and attenuation of 
recurrences in manic depressive illness, and have lead to the daily 
administration of Li to some patients for periods of years (4). 
Also in 1949, however, two investigators reported a total of 
eleven cases of Li toxicity, including three deaths, when Li was 
used as a salt substitute for patients on salt restricted diets (29, 
60). Early studies on Li toxicity in experimental animals were 
done by Radowski et al (105) and Schou et al (113). Both groups 
concluded that the principal toxic action of Li is on the kidney 
and that this toxicity was manifested by a pronounced polyuria, 
loss of sodium (Na), and renal tubular damage. These conclusions 
have been confirmed and expanded by studies that will be reviewed 
below. 
The experiments presented in this report were designed to 
investigate the effect of the amiloride, a diuretic that appears to 
block the cellular entry of Li, on the polyuria and the renal 
-1- 
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morphologic changes associated with chronic Li administration in 
the rat. The following literature review is intended as an intro¬ 
duction to current information about Li, Amiloride, and the effects 
of these agents on the kidney. 
2. Lithium 
Pharmacokinetics and Renal Handling 
Because Li is not metabolized, its pharmacodynamics are determined 
solely by absorption, distribution, and excretion. Li is rapidly 
and completely obosrbed from the G.I. tract (1,2). However, plasma 
levels of Li (P .) peak earlier and are higher if Li is given 
L1 
parenterally (139,143). Li is not bound to plasma proteins (49,131) 
and is distributed throughout the total body water (2,115). 
Although Li can be detected in feces, sweat, sputum, sperm, 
and breast milk, 95 to 100% of ingested Li is excreted by the 
kidney (2,147). Urinary excretion is rapid at first, with 33 - 67% 
of a single oral dose excreted in 6-8 hours, but the remainder is 
excreted slowly over the next 10-14 days. On daily administration 
an equilibrium between the amount of Li ingested and excreted is 
not reached for 5-6 days (147). Slow entry and exit of Li into 
the intracellular space probably account for both the prolonged 
excretion and the slow establishment of an equilibrium state (121). 
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Because Li is not bound by plasma proteins it is freely 
filtered by the glomerulus. The renal clearance of Li (C .) at 
L l 
P . below 2.0 mEq/L is 10-40 ml/min in humans (2,134,126) and 
L i 
.10-.30 ml/min/lOOg BW in the rat (141,143). Fractional excretion 
of Li (FEt . ) , defined as C . /CT ... or C . /c . . , is 0.20 
to 0.40 in both humans and rats (2,127,136). This implies that a 
large portion of filtered Li is reabsorbed. How the kidney re¬ 
absorbs Li is not completely understood, but it appears that distinct 
segments of the nephron handle Li differently and that Li does not 
mimic perfectly any endogenous ion during its passage through the 
renal tubule. 
A considerable amount of data suggest that Li is reabsorbed 
primarily by the proximal tubule and that the proximal tubule 
handles Li much as it does Na. The FE . of 0.20 to 0.40 corre- 
Li 
sponds to the fraction of filtered Na delivered from the proximal 
tubule (135). In addition, pertubations that are thought to alter 
proximal tubular Na handling also alter C Agents that increase 
Na delivery from the proximal tubule, either by causing an osmotic 
diuresis (urea), or by inhibiting proximal Na reabsorption (acet- 
azolamide), also increase the FE . in man and rat (126). Changes 
L i 
in blood volume alter proximal tubular handling of Na by mechanisms 
that are independant of glomerular filtration rate (GFR). Rats 
with diminished extracellular fluid volume will reabsorb a larger 
V, 
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fraction of filtered Na and water in the proximal tubule (34,128). 
Similarly, rats that are treated with Li that are volume contracted 
from water and Na loss have a reduced C . as a result of both a 
Li 
decrease in GFR and FE . (146). Volume expansion from saline 
L l 
infusion will reduce proximal Na reabsorption and will increase FE ^ 
in the absence of changes in creatinine clearance (135). 
Studies with diuretics that act primarily on sites other than 
the proximal tubule have yielded conflicting results which may be 
accounted for by differences in the acute and chronic effects of 
these agents. The acute administration of thiazides or spirolactone 
in man does not alter C . (126), which suggests that there is no 
L l 
distal tubular reabsorption of Li, at least none that is inhibited 
by these agents. However, the chronic administration of thiazides 
in man and rat decreases C . (74,103,138) because of the volume 
L i 
contraction that results from the chronic administration of these 
agents (41). The intravenous administration of furosemide in man 
initially increases C . (126). This observation suggests that Li 
L l 
may be reabsorbed by the loop of Henle, where furosemide has its 
primary action. However, the acute administration of furosemide 
may inhibit proximal Li reabsorption, as it inhibits proximal Na 
reabsorption (117). After one hour of furosemide administration 
C . decreases as volume contraction ensues and the proximal tubular 
reabsorption of Na and Li increases (126). These examples illustrate 
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the difficulty of determining the sites of Li reabsorption on the 
basis of experiments that alter nephron function. Every inter¬ 
vention used in the experiments cited above has complex and far 
ranging effects on renal function and cannot selectively alter only 
a distinct portion of the nephron. 
The establishment of a corticopapillary gradient for Li 
analogus to the one for Na (45,124) indicates that papillary tubular 
segments - the pars recta, the ascending limb of the loop of Henle, 
the medullary and papillary collecting ducts - are involved in Li 
reabsorption. Stop flow studies in dogs with P . between 10 and 21 
Ll 
mEq/L demonstrated some distal tubular reabsorption, but no secre¬ 
tion (72). However, distal tubular Li reabsorption has not been 
observed at less toxic levels of P . with techniques that may have 
1j 3. 
more validity than stop flow studies. Micropuncture experiments 
have been done only recently because of the difficulty of measuring 
Li in nanoliter samples. Free flow micropuncture experiments (62) 
in rats with P . of 3.9 mEq/L demonstrated that 56% of filtered Li 
L1 
is reabsorbed in the proximal tubule and 18% in the pars recta or 
ascending limb. There was no evidence that Li was reabsorbed beyond 
the early distal tubule. 
Steele et al have argued that,since Li has profound effects on 
distal tubular function and morphology ,Li is probably reabsorbed 
across distal tubular cells (127) . However, Li could enter cells 
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across the serosal membrane. Since stable isotopes of Li do not 
occur, there are no data on the cellular uptake of Li from the 
serosal and luminal side in renal epithelia. Which membrane Li 
crosses to enter the renal cell has not been conclusively demon¬ 
strated by other methods (60, 120). Even if Li enters the cell 
across the luminal membrane, Li must be transported out of the cell 
across the serosal membrane for significant reabsorption to take 
place. 
In summary, available data indicate that, similar to Na, Li 
is reabsorbed primarily in the proximal tubule and in the pars 
recta or ascending limb. However, in contrast to Na, Li reabsorption 
in the distal nephron has not been demonstrated to be quantitatively 
important. The relationship between the renal handling of the two 
ions may explain why inadequate Na intake is associated with severe 
Li toxicity in man and experimental animals (29,60,105,113,140). 
Extracellular volume contraction from Na depletion reduces C ^ and 
increases P . both by decreasing GFR and increasing fractional 
Ll 
proximal tubular Li reabsorption. 
Effect on Water and Electrolyte Metabolism 
Sodium. At therapeutic P„^ in humans (0.3 to 1.2 mEq/L) (3) 
Li 
Na balance is negative for the first day of treatment, but is 
positive the next 4-5 days and may result in net Na accumulation (10, 
98,147). However, at toxic P . ( 1.5 mEq/L), balance studies in 
Ll 
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humans (11) and experimental animals (137, 140) demonstrated sig¬ 
nificant renal Na wasting with a negative Na balance. Free flow 
micropuncture studies during acute LiCi infusion in rats showed an 
increase in FE^ over that of controls (62). Rats with free access 
to a hypertonic (0.46M) NaCl solution while on chronic oral Li 
administration will survive a dose of Li that is toxic to rats 
without access to increased dietary intake of sodium (139, 143). 
These data suggest that Li alters renal Na handling and causes 
Na depletion if there is no increase in dietary intake of sodium. 
Thompson et al argue that Li intoxication results from a Li induced 
Na depletion that, for reasons explained above, causes a decreased 
C . and an increased P . . A greater natriuresis occurs at the 
Ll Ll 
higher P and a vicious cycle ensues unless excess NaCl is 
available (143, 145). 
Li might alter Na balance by displacing Na from both the intra¬ 
cellular and extracellular fluid compartments. However, Schou 
et al (113) and Radomski et al (105) dismissed this as insufficient 
to explain Li-induced natriuresis. An increase in uric acid ex¬ 
cretion - a substance reabsorbed primarily in the proximal tubule - 
suggests that there is diminished proximal tubular reabsorption (89). 
In addition, Brattleboro rats without endogenous ADH given acute 
infusions of Li have increased urine flow and increased free water 
clearance compared to controls (107). This is attributed to a 
• 
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Li-induced inhibition of Na and water transport in the proximal 
tubule resulting in increased delivery of filtrate to the ascending 
limb and increased generation of free water (46, 107). This 
increased free water clearance following Li administration in the 
Brattleboro rat implies that the transport functions of the loop 
of Henle are grossly intact (46, 107). A normal corticopapillary 
gradient for Na also indicates that there is relatively normal loop 
function (45, 124). 
A free flow micropuncture study demonstrated that acute 
administration of LiCl decreases proximal Na reabsorption (55). 
However, the loop of Henle fully compensated for the increased load 
of Na since the fraction of Na delivered to the distal tubule was 
the same as that of controls. In this study, Na reabsorption in 
the distal tubule and collecting tubule was reduced in animals 
receiving LiCl. Therefore, the natriuresis observed in the acute 
administration of LiCl is likely to be due primarily to decreased 
Na reabsorption in the distal nephron. The mechanisms by which 
sodium balance becomes positive during chronic Li administration in 
man are not yet well understood. 
Li may reduce Na reabsorption by competing with Na for trans¬ 
port pathways. Studies with Na in toad urinary bladders, an in 
vitro model of the mammalian collecting duct, demonstrate that Li 
is transported by Na selective channels in the mucosal membrane (65, 
83, 111). However, one of these studies indicates that Li inhibits 
■ 
- 
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Na reabsorption across these channels to a degree beyond that 
accounted for by competition (111) suggesting that Li exerts a 
toxic effect on Na transport machinery. 
Plasma renin activity and plasma aldosterone levels are 
elevated in animals given sufficient Li to cause natriuresis (12, 
56) which indicates that there is release of renin and aldosterone 
in response to this natriuresis. However, Li reduces aldosterone 
stimulated Na reabsorption in the toad urinary bladder and in intact 
and adrenalectomized rats (9, 11, 31, 142). Therefore, tubular 
unresponsiveness to aldosterone may be responsible for at least a 
portion of the Li-induced natriuresis. 
Potassium. Li administration is associated with a transient 
kaliuresis in humans (9) and experimental animals (49, 71), though 
the magnitude of the kaliuresis is less than that of the natri¬ 
uresis and is not associated with changes in serum potassium (K) 
in humans (9) or rats (89). A micropuncture experiment in rats 
during acute Li infusion demonstrated an increase in the fractional 
excretion of K (62). Acute Li administration also reduced the 
maximal secretion of K in rats following K loading. 
How Li alters renal K handling has not been well defined. The 
micropuncture study cited above demonstrated decreased proximal K 
reabsorption (62). However, the Loop of Henle appeared to compensate 
for the increased K load, as it does for an increased Na load, 
4 
-10- 
because an equal percentage of filtered K+ is delivered to the 
distal tubule. Marked K secretion then occurs in the distal tubule, 
possibly because of an increased urine flow rate (51). Inhibition 
of the action of aldosterone by Li could account for the inhibition 
of maximal K secretion following K loading. 
Hydrogen Ion. Li also impairs urinary acidification at thera¬ 
peutic P . in both humans (62) and experimental animals (122), 
though it has never been associated with a significant acidemia in 
humans (85). The site of impairment appears to be the distal 
tubule because acidification of the urine during Li administration 
was impaired even at low serum bicarbonate concentrations. Whether 
this impairment is due to diminished secretion of hydrogen ion, 
excessive back diffusion, or decreased cellular generation of 
hydrogen ion is not established. 
Water. Radomski et al (105) and Schou et al (113) observed 
that Li caused experimental animals to void large volumes of hypo¬ 
tonic urine. Schou et al (113) demonstrated that rats with PT . 
- Li 
of between 0.2 and 0.7 mEq/L had a polyuria six to ten times that 
of controls. This polyuria was unresponsive to exogenous Pitressin. 
Angrist reported in 1970 that 2 patients with therapeutic P . had 
urine volumes up to 3.5 L/day and low urine osmolarities unresponsive 
to water deprivation and Pitressin (6). Other case reports describ¬ 
ing polyuria and polydipsia associated with Li therapy followed (84, 
119\ but this was not recognized as a common syndrome in Li therapy 
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until Forrest et al (45) reported that, in a series of 96 patients 
on Li, 12% had polyuria greater than 3 L/day and 40% had symptoms 
of increased thirst and water intake. 
Lithium may induce polyuria by 1). creating a defect in the 
concentration of urine (primary polyuria), 2). by directly stimu¬ 
lating thirst (primary polydipsia), or, 3). by causing both of 
these phenomena to occur. There is evidence that Li does cause a 
primary polydipsia in rats. Smith et al found that rats given LiCl 
by stomach tube had significantly greater water intake than controls 
prior to the development of hemoconcentration or detectable hypo¬ 
volemia (123). However, a defect in urinary concentrating ability 
appears to be the major factor contributing to Li induced polyuria. 
In ten patients with Li induced polyuria studied by Forrest four 
could not concentrate their urine above plasma osmolality () in 
response to water deprivation (45). Patients with only primary 
polydipsia always concentrate their urine above P0sm when deprived 
of water (46). 
In order to concentrate urine many components of renal function 
must be intact. There must be adequate circulating levels of ADH 
and an appropriate response to this hormone by the cells of the 
cortical and medullary collecting ducts. Even if ADH is present 
and the collecting duct is responsive to this hormone, a normal 
corticomedullary osmotic gradient must be established and maintained. 
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To establish a hypertonic medullary interstitium an adequate amount 
of Na must be filtered by the glomerulus and delivered from the 
proximal tubule to the ascending limb of the loop of Henle. Na 
transport in the ascending limb cannot be impaired. Conceivably, 
Li could alter any one or a combination of these components of the 
urinary concentrating mechanism to cause polyuria. 
Agents that impair urinary concentrating ability by inhibiting 
the establishment of a corticomedullary gradient also impair the 
excretion of a free water load, since the renal generation of 
hypotonic urine depends on adequate delivery of filtrate to the 
ascending limb and normal Na reabsorption in this tubular segment. 
Li administration does not significantly alter the normal 
corticopapillary gradient for Na in rats (45) and dogs (124). 
Solute free water clearance in humans (119) or subhuman primates (151) 
is not impaired by Li. Both of these observations indicate that 
ascending limb Na reabsorption is intact. Free flow micropuncture 
studies in rats demonstrate that the fractional excretion of water 
actually increases in rats infused with LiCl, as compared to rats 
infused with NaCl. As discussed above, proximal tubular reabsorption 
of filtrate is decreased during Li administration, but the loop of 
Henle appears to reabsorb the added Na delivered to it. The 
consequence is that there is a larger volume of solute free water 
generated and delivered to the collecting duct, and this may 
' 
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contribute to Li-induced polyuria. Brattleboro rats without 
endogenous ADH given intraperitonealdoses of LiCl have an increased 
urine flow compared to control Brattleboro rats (12, 107). Since 
neither group has endogenous ADH, the increased urine flow must be 
secondary to a factor independent of ADH. Acute infusions of LiCl 
to anesthetized Brattleboro rats also increases solute free water 
clearance, establishing that this increase in free water excretion 
was not due entirely to a Li induced primary polydipsia (107). 
Li appears to cause polyuria primarily by inhibiting the 
action of ADH on the collecting tubules. The majority of patients 
with urinary concentrating defects while on Li do not respond, or 
respond subnormally to exogenous ADH (45, 119). Patients with Li 
induced polyuria that have plasma vasopressin levels measured usually 
have high levels that are consistent with a nephrogenic diabetes 
insipidus (101). Most animal models also demonstrate an inhibition 
of ADH by Li. Normal rats (45), BB rats (139), and subhuman 
primates (128) given Li have blunted responses to exogenous ADH 
compared to controls. Singer et al have demonstrated that Li 
inhibits ADH stimulated water flow in the toad urinary bladder (120, 
121) . 
Only certain portions of the collecting duct may be sensitive 
to the action of Li. Carney et al (23) could show no change in ADH 
dependant water permeability in isolated perfused papillary 
- 
' 
• , 
■ 
• - 
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collecting ducts of rats with Li induced polyuria. Kudo and Rocha 
confirmed this in the rabbit papilla, but in addition demonstrated 
that Li impaired ADH stimulated water flow in cortical collecting 
tubules (80). i 
ADH increases water permeability by first interacting with 
a vasopressin sensitive adenylate cyclase receptor complex (38, 58). 
Most of these receptors are located in the cortical and medullary 
collecting ducts (79, 94, 153). In response to hormone binding, 
cAMP is generated intracellularly and acts through, as yet, unknown 
pathways to increase water permeability of the luminal membrane (38, 
58) . 
There is evidence that Li inhibits the action of ADH both 
proximal and distal to the generation of cAMP. In the toad urinary 
bladder. Singer found that Li inhibited ADH induced water flow, but 
not dibutyrl cAMP stimulated water flow (119). Dousa demonstrated 
that Li had an inhibitory effect on the stimulation of adenylate 
cyclase by vasopressin in homogenates of human renal medullary 
tissue (36). These studies argue for an effect of Li to decrease 
cAMP generation. However, Li-induced polyuria in rats is only 
partially reversed by intravenous dibutyryl cAMP (45, 89). In 
addition, dibutyryl cAMP mediated increases in water permeability 
were impaired in isolated perfused cortical collecting tubules 
of rabbits with Li-induced polyuria (80). These later studies 
demonstrate an impaired action of ADH distal to cAMP generation. 
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In a minority of patients with Li-induced polyuria there 
appears to be a component of central diabetes insipidus, i.e., a 
defect in synthesis, storage, or release of vasopressin. Forrest 
et al and Singer et al reported a total of three patients who 
increased their urinary osmolality after exogenous ADH (45, 119). 
In a series of 48 patients on Li one patient had an inappropriately 
low plasma vasopressin level (101). Li is concentrated in the 
central nervous system and has been shown to deplete the pituitary 
neurosecretory material (12). However, this depletion may be 
secondary to chronic stimulation for ADH release caused by a nephro¬ 
genic diabetes insipidus. 
Recently, there have been several reports documenting a total 
of seven cases of nephrogenic diabetes insipidus persisting months 
to years after the discontinuation of Li (43, 48, 58, 104, 118). 
These reports suggest that irreversible or slowly reversible morpho¬ 
logic damage may contribute to Li induced polyuria. 
In summary, Li disturbs several components of renal function, 
especially distal tubular function. There is an initial natriuresis 
and kaliuresis, an impairment in maximal potassium secretion, and 
a distal tubular urinary acidification defect. A pronounced poly¬ 
uria occurs in some patients primarily because of a Li-induced 
nephrogenic diabetes insipidus, perhaps complicated by morphologic 
damage, reduced proximal Na reabsorption, and, in a minority of 
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patients, a central diabetes insipidus. Although the disturbances 
in potassium and hydrogen ion metabolism are not important clinically, 
the polyuria and the natriuresis can potentially cause volume 
depletion, reduced clearance of Li, and, hence, dangerous Li 
toxicity (145, 146). 
If Li-induced polyuria becomes bothersome to the patient it 
can be treated successfully with the administration of thiazides (85). 
However, thiazides do not alter the Li-induced impairment in the 
tubular response to vasopressin. Rather, by causing mild natriuresis 
and volume contraction, thiazides may decrease GFR and increase 
proximal tubular reabsorption so that less filtrate is delivered to 
the distal nephron (41). Unfortunately, thiazide diuretics reduce 
the renal clearance of Li and predispose to the development of Li 
toxicity (69, 88, 103, 138). 
Morphologic Lesions Associated with Lithium 
Renal histopathologic changes after Li administration were 
first reported by Radomski et al in 1950 (105). Dogs were given 
LiCl orally for 2 to 20 weeks and had PT . of between 3.3 and 6.2 
mEq/L. The animals had renal cellular changes confined to the 
distal and collecting tubules with flattened, atypical, occasionally 
necrotic epithelia. Schou et al also reported renal tubular damage 
in rats given intraperitoneal LiCl chronically, but the damage 
was confined primarily to the proximal tubule (113) . Iavorskii et al 
. 
. 
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injected rats intraperitoneally with 200 mg/kg BW LiCl daily for 6 
days, producing acute renal failure, oliguria, and marked nonfocal 
sclerosis of renal tissue (73). 
Evan and Ollerich published the only ultrastructural study of 
Li-induced changes in renal morphology (44). They injected rats 
with 0, 10, 30, or 100 mgLiCO^/kg BW daily for 12 to 60 days. P . j Li 
was not reported. The kidneys were fixed by vascular perfusion 
through the left ventricle with a 325 mOsm solution of 1% gluteral- 
dehyde. Animals that received the highest dosage became toxic and 
died before 60 days. This group had the most severe changes of 
mitochondrial swelling and dilatation of rough endoplasmic reticulum 
in all portions of the nephron, and karyolysis, karyorrhexis, apical 
cytoplasmic rarefaction, and cell hypertrophy in the distal nephron. 
It was not noted if these observations were limited to the cortex,, 
or included the medulla. However, because artifacts may be caused 
by fixatives with different osmolalities than the tissue (91), 
Evan's fixative solution was probably only adequate for evaluation 
of the cortex. 
These previous studies are of questionable utility in predicting 
what type of morphologic changes might occur in patients on long 
term Li therapy. All involved parenteral Li, with higher peak 
plasma levels of Li, and/or P . in the toxic range with accompanying 
L1 
toxic symptoms. 
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There are isolated case reports of biopsy or autopsy material 
from patients with acute Li intoxications. Lindop and Padfield 
noted pleomorphism and atypia of the distal tubular cells in a 
patient dying of a drug overdose after three years on Li (87). 
Lavender et al reported marked changes in tubular cells and tubular 
dilatation in a biopsy from a patient with acute renal failure who 
had been on Li for two years (82). However, acute intoxication 
may be responsible for these lesions. In addition, there were no 
age matched controls. 
In 1977 Hestbech et al published results suggesting that chronic 
Li therapy may be associated with nonspecific lesions of chronic 
nephropathy (67). They reported on a series of 14 patients on Li 
who had been biopsied and their specimens compared to specimens from 
9 donor and 4 postmortem kidneys. The duration of Li therapy was 
between 1 and 15 years and the P . between .60 and 1.30 mEq/L. 
L i 
However, 10 of the patients had had one or more toxic episodes, so 
that they did not constitute a representative selection of Li treated 
patients. In comparison to controls, there was significantly more 
focal cortical fibrosis, diffuse medullary fibrosis, sclerotic 
glomeruli, and tubular atrophy in the Li treated patients. Three 
kidneys in the Li treated group had multiple cortical cysts. There 
was a significant inverse correlation between the degree of 
interstitial fibrosis and the creatinine clearance, but no significant 
correlation between the amount of lesions and the duration of therapy. 
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Burrows (20) reported that in each biopsy from 6 patients on 
Li for between 4 months and 9 years there was ballooning of cells 
and vacuolation of the cytoplasm occuring primarily in the distal 
tubules and collecting ducts. Affected tubules had cells with PAS 
staining granules within the cytoplasm. In patients that had 
received Li for longer than 6 years there was also interstitial 
fibrosis, tubular atrophy, and sclerotic glomeruli. Despite the 
lesions, there was no increase in serum creatinine in any of the 
patients. However, some of these patients had previously been on 
other drug regimens. In addition, the study did not compare the 
specimens with controls. 
Rafaelson et al (106) have been conducting an ongoing functional 
and morphologic study of patients in Scandinavia. Morphologic 
findings were divided into clearly pathological, borderline, and 
normal for the lesions described by Hestbach et al (67). Of 37 
patients, 6 had clearly pathologic lesions, 11 were graded as border¬ 
line, and 20 were normal. Pathologic changes are associated with 
polyuria greater than 3 L/day and reduced creatinine clearance. 
However, there was no significant correlation between pathologic 
lesions and duration of therapy. 
Recently, Hestbach et al (68) have reported that prolonged Li 
administration to rats causes renal lesions similar to those seen 
in humans. Wistar rats given oral LiCl for nine weeks at doses 
' 
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sufficient to achieve P . of 1.1 to 1.3 mEq/L had focal cortical jLll 
interstitial fibrosis and altered cells in the distal tubules and 
collecting ducts. An animal model of renal morphologic changes 
induced by chronic oral Li administration would be useful in 
investigating these lesions. However, there must be proper controls 
because spontaneous changes similar to those reported by Hestbach 
et al can occur in some rat species (18). 
These initial reports have stimulated great concern about 
the possible hazards of chronic Li therapy in man and have generated 
a number of clinical and laboratory investigations. 
However, it is not established that chronic Li therapy that 
is uncomplicated by intoxication actually causes these morphologic 
changes. The lesions are not specific for lithium and many of the 
patients in these studies have been exposed to other drugs. The 
Scandinavian studies of Rafaelson and Hestbach may not be predictive 
for patients in the U.S. since Scandinavian patients often receive 
their daily Li in a single dose rather than in divided doses as 
is practiced in the U.S. This dosage schedule would cause higher 
peak serum Li levels. Finally, it is not known what significance 
these lesions have in terms of renal function. Some patients, but 
not all, with morphologic changes have reduced C and urinary 
LT0 cl L- 
concentrating defects. However, Li induced polyuria is usually 
reversible and, although there is an association between lesions 
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and lowered creatinine clearance, patients that developed terminal 
renal failure because of Li treatment have not been reported (76). 
3. Amiloride 
Amiloride is a mild oral diuretic that is not yet licensed for 
use in the U.S. It has a weak natriuretic effect that is syner¬ 
gistic with thiazides and acetazolamide, but is not mineralocorti- 
coid dependent (8). However, it has a powerful potassium sparing 
action that completely suppresses potassium secretion by the distal 
tubule (39). In addition, it impairs urinary acidification by 
decreasing distal tubule hydrogen ion secretion, but does not 
produce a metabolic acidosis (55). In usual doses, amiloride does 
not have important pharmacologic actions except those related to 
renal tubular function (97). 
The major sites at which amiloride acts are the distal tubules 
and collecting ducts. Micropuncture studies in rats could demonstrate 
no change in GFR with amiloride and no inhibition of proximal 
tubular or ascending limb Na reabsorption (39). However, distal 
tubular Na reabsorption was modestly reduced and distal tubular 
potassium secretion was completely suppressed. Amiloride appears 
to act primarily from the luminal membrane in both rats (93) and 
toad urinary bladders (14, 42, 130). 
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Numerous studies in transport epithelia demonstrate that 
amiloride reversibly inhibits Na permeability of the mucosal 
surface (14, 42, 130). Electrophysiologic analysis suggests that 
amiloride binds competitively with Na to the Na channel of the 
mucosal border and blocks entry of any ion normally transported 
by that channel (130) . 
The fall in sodium permeability of the distal tubule causes 
a reduction in transepithelial potential difference, one of the 
driving forces for potassium secretion (52). Garcia and Giebisch 
demonstrated that this change in potential difference fully accounted 
for the reduced potassium secretion (51). Potassium secretion 
returned to normal when the electrical effects of amiloride were 
reversed by external current application (52). 
In transporting epithelia, Li appears to enter cells from the 
mucosal membrane through an amiloride sensitive Na channel (111) . 
However, there is no conclusive evidence that demonstrates that 
Li enters renal tubular cells primarily from the luminal membrane. 
In toad bladders, results have been contradictory, with Singer 
showing inhibition of ADH stimulated water flow only with mucosal 
Li (119, 120), and Harris and Jenner showing inhibition only with 
serosal Li (61). Li may alter renal function and morphology by 
substituting imperfectly for other cations that normally participate 
in the establishment of electrochemical and osmotic gradients, or 
- 
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by modifying the cellular microenvironment and altering the physico¬ 
chemical properties of biologic macromolecules (121, 152). Theo¬ 
retically, amiloride might attenuate Li-mediated changes in renal 
function and morphology by limiting the entry of Li into the distal 
tubular and collecting duct cells (120, 129). 
Several investigators have observations that support this 
hypothesis. Singer and Franko (120) demonstrated that when amiloride 
is added to the mucosal solution in toad bladders it reduces lithium's 
inhibition of ADH. In addition, Herrara et al found that amiloride 
decreased tissue Li accumulation and increased tissue potassium 
content compared to bladders exposed only to Li (66). 
Webb et al observed that amiloride partially prevented the 
defect in free water reabsorption caused by acute Li infusion in 
subhuman primates (151). Pretreatment with intravenous amilor de 
followed by continuous amiloride infusion decreased the reduction 
of solute free water reabsorption caused by infusions of LiCl that 
uave a P . of 1.8 and 3.4 mEq/L. Martinez-Maldonado et al observed 
Li - 
a similar improvement in free water reabsorption with amiloride in 
rats receiving acute infusions of Li (90). The experiments were 
designed to investigate both free water clearance and free water 
reabsorption during Li infusion with or without intravenous amiloride. 
Maximal P . was very high: 54 mEq/L in the free water reabsorption 
L i 
experiments and 15 mEq/L in the free water clearance studies. At 
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these P ., Li inhibited both free water reabsorption and free water 
Li 
clearance. Amiloride partially reversed the inhibition of free 
water reabsorption, but had no effect on free water clearance. 
The present investigation was initiated to characterize with 
light and electron microscopy the renal morphologic lesions 
associated with chronic Li administration in the Sprague-Dawley 
rat. The experiment was also designed to study the effect of 
amiloride on Li mediated changes in urinary concentration and 
morphology. In addition, Li and amiloride were administered to 
Brattleboro rats in an attempt to determine the mechanism by which 
amiloride alters Li induced polyuria. 
■ 
MATERIALS AND METHODS 
1. Chronic Administration of Lithium and Amiloride to Sprague- 
Dawley Rats 
Twenty-six male Sprague-Dawley rats initially weighing 108 
to 131 grams were housed in individual cages in a room with a 12 
hour light-dark cycle. Each cage was equipped with a food con¬ 
tainer, two Water bottles, and a urine collection pan. Rats were 
fed daily 10 to 15 grams of a prepared food containing per kg 490 g 
sugar, 100 g lard, 300 g casein, 50 g corn oil, 6.04g(100 mmol) 
NaCl, 11.60 g K^HPO^, 30.39 g vitamin-mineral mix, 20 g. vit. diet 
fortification mixture. To avoid Li intoxication, all rats had free 
access to both tap water and a 0.46 M NaCl solution (143). 
After a five day equilibration period, the rats were divided 
into four groups: group 1 (controls) (n=6) received the control 
diet, group 2 (Li) (n=6) received LiCl 4-6 mmol/kg BW/day in their 
food, group 3 (Ami) (n=6) received amiloride (supplied by Merck, 
Sharp, and Dohme) 6 mg/kg BW/day in their food, and group 4 (Li/Ami) 
(n=8) received both LiCl 3-6 mmol/kg BW/day and amiloride 6 mg/kg 
BW/day in their food. LiCl was adjusted to establish plasma Li 
concentrations within the therapeutic range (0.3 to 1.2 mEq/L) (3)y 
and to maintain plasma Li concentrations in the Li and Li/Ami 
. 
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groups at comparable levels. An additional 6 rats were rendered 
polydipsic and polyuric by allowing access to a 5% glucose solution 
instead of tap water, which rats drink in large quantities pre¬ 
sumably because of the taste of the solution. To enhance the poly¬ 
dipsia they were fed only 10 g of the control diet daily. The 
urine was tested for the presence of glucose to insure that these 
rats were not glucosuric. The duration of the study was eight 
weeks. 
Monitoring of Renal Function 
Total fluid intake was measured by weighing each bottle before 
and after each monitoring period, determining the difference in 
weight, and then converting the units from grams to milliliters. 
Total fluid intake was expressed as ml/day/lOOg BW. Because total 
fluid intake served as an indirect measurement of urine flow rate, 
this procedure was done carefully to insure accuracy. Bottles 
were filled completely to the top before each monitoring period, and 
movements of the racks with the metabolic cages were kept to a 
minimum. The error from evaporation and leakage was determined by 
removing measured amounts of water from bottles that were placed in 
empty racks handled similarly to those the animals were housed in. 
The additional loss was then measured 24 hours later. 
A 24 hour urine specimen was collected on days 7 and 57 while 
rats had access to water, the NaCl solution, and food. A urine 
. 
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flow rate was calculated from the volume of these 24 hour specimens 
and expressed as ml/hour/100 g BW. Urine osmolality could not be 
determined from these samples because of the contamination of the 
urine with food. To measure urine osmolality, a 6 hour urine 
specimen was collected from 12 MN to 6 AM on days 34 and 51 while 
rats had access to water and the NaCl solution, but not to food. 
Urine osmolality was determined on these specimens and expressed 
as mOsm/kg H^O. A 12 MN to 6 AM time period was chosen because 
fluid intake and urine flow rates in rats are highest at night. 
The response of these animals to DDAVP, an ADH analogue (112, 149), 
was tested by injecting DDAVP 1500 pg/rat subcutaneoulsy at 6 AM, 
12 N, 6 PM and 12 MN before a 12 MN to 6 AM urine collection on day 
52, and determining the urine osmolality on these specimens. Urine 
osmolality was determined by freezing point depression on an 
Advanced Instruments osmometer. All urine collections were done 
under mineral oil to avoid evaporation. 
Blood for plasma Li concentrations was collected in micro¬ 
hematocrit tubes from the cut end of the tail vein under light ether 
anesthesia in the morning on days 8, 16, 29, 43 and 57. Li con¬ 
centrations were determined with a Perkin Elmer atonic absorption 
spectrophotometer and expressed in mEq/L. Hematocrit was determined 
on a Critocap hicrohematocrit tube reader after the microhematocrit 
tubes were spun for 3 minutes in a centrifuge. 
- 
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To test the feasibility of administering Li and amiloride 
in the food, and monitoring fluid intake, urine flow rate, and 
plasma Li concentration, a pilot study involving a smaller number 
of male Sprague-Dawley rats (n=18) was done under similar con¬ 
ditions. Creatinine clearances were determined in 12 of these 
18 rats. A 24 hour urine specimen was collected for urine creati¬ 
nine concentration and blood was obtained from the renal vein 
under Inactin anesthesia for serum creatinine concentration. Both 
urine and serum creatinines were determined on a Technicon auto 
analyzer. Because of technical difficulties involved in obtaining 
sufficient blood from animals that are perfused with fixatives 
for electron microscopy, creatinine clearances were not performed 
in the larger study. 
Renal Morphology 
Three animals in each of the five groups (four in the Li/Ami 
group) had renal tissue fixed for ultrastructural analysis by 
vascular perfusion after 8 weeks. Analysis of ultrastructure was 
confined to the cortex so that the osmolalities of the fixative 
and the tissue under investigation would be approximately the same. 
Medullary and papillary tissue osmolality varies widely in animals 
that have different degrees of urine flow, and artifacts caused by 
differences in osmolality between the tissue and the fixative can 
result (91). The exact composition of the fixative solutions for 
'i-Os 
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the cortex was as follows: 1) The rinse contained mammalian 
Ringers in 3% dextran T40. 2) The perfusion solution was a modified 
Karnovsky's fixative containing 4% paraformaldehyde, 5% gluteral- 
dehyde, diluted in a 1:3 ratio with 0.1 M solium cacodylate 
buffer (78) . Osmolality was adjusted to 300 mOsm/kg H.^0 by the 
addition of 0.075 M sucrose with 3% dextran T40. 3) The fixative 
solution was undiluted Karnovsky's fixative. 4) The wash buffer 
contained 0.1 M sodium cacodylate and 0.075 M sucrose. 
Exogenous ADH will cause morphologic changes in cortical 
collecting ducts of ADH deficient Brattleboro rats - cell swelling, 
and enlargement of the space between the basolateral infoldings (153) . 
To minimize the differences in morphology between groups that 
might be due to different levels of ADH, each rat was given a supra 
maximal dose of DDAVP (1500 pg/rat) subcutaneously one hour before 
perfusion (112). 
Under Inactin anesthesia the abdominal aorta was catheterized, 
the aorta clamped proximal to the renal arteries, and the left 
renal vein severed. Following rapid perfusion for 30 seconds with 
the rinse solution, 50 ml of perfusion solution was run through the 
vascular system at physiologic pressure (91). The left kidney 
was then removed and sectioned transversely through the hilus. 
Several sections of cortex were removed, immersed in fixative, and 
coded. The right kidney was also removed and placed in formalin for 
light microscopy studies. 
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Tissue for electron microscopy was then post-fixed with s- 
Collidine buffered 1.33% 0 0., washed in 0.2 M s-Collidine buffer, 
stained en bloc with uranyl acetace-oxylate (96), washed in graded 
ethanols, and embedded in Epon. A 1 M "thick" section stained 
with toluidine blue--Azure II was examined by light microscopy to 
locate areas with a large proportion of collecting tubules. An 
ultramicrotome (LBK Huxley) was used to obtain ultrathin sections. 
These sections were stained with uranyl acetate and lead citrate 
for examination with a Zeiss EM 10B electron microscopy that was 
in the laboratory of Daniel Biemesderfer. Collecting tubules were 
identified by the presence of light (principal) cells, characterized 
by a light cytoplasm and a low density of mitochondria, and dark 
(intercalated) cells, characterized by a dark cytoplasm, a high 
density of mitochondria, and apical vesicles (153, 99). Rep¬ 
resentative sections were photographed at magnifications between 
X 6,250 and X 10,000. Between six to eight coded photomicrographs 
of collecting ducts from each rat were evaluated by two observers 
(T. M. and D. B.) independently for qualitative changes in ultra- 
structure. 
In two animals in each of the five groups, the right kidney 
was removed under Inactin anesthesia, sectioned cransversely, and 
placed in formalin without prior vascular perfusion. Formalin 
fixed kidneys from both perfused and nonperfused animals were 
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paraffin embedded, cut in 4 m thick sections and stained with 
hematoxylin and eosin. 
All specimens were coded and evaluated blindly. Light micro¬ 
scopy specimens were assessed by a semiquantitative method for 
lesions of interstitial inflammation characterized by inflammatory 
cells, tubular damage, or fibrosis. Score 0 was used when there 
was neither cellular infiltrates nor fibrosis. Scofe 1+ was used 
when there was no more than one focal area of infiltration. Score 
2+ was used when there were several small areas of infiltration. 
Score 3+ was used when there were numerous small areas of infil¬ 
tration or several large areas of infiltration. Score 4+ was used 
when there was infiltration and fibrosis. Each slide was graded 
by two observers (T. M. and M. K.) on two separate occasions and 
the scores averaged. 
2. Chronic Administration of Lithium and Amiloride to Brattleboro 
Racs 
Lithium and Amiloride were administered to ADH deficient 
Brattleboro rats (148) to determine if the effect of amiloride on 
Li induced polyuria was due to a mechanism not dependant on the 
presence of ADH. Fifteen male Brattleboro rats initially weighing 
74 to 121 grams were placed in identical conditions as the previous 
' 
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study. All rats were observed to drink 50% or more of their body 
weight per day before beginning the study. 
After a five day equilibration period the rats were divided 
into three groups of 5 animals each: group 1 received the control 
diet, group 2 (Li) received LiCl in their food, group 3 (Li/Ami) 
received LiCl and amiloride 6 mg/kg BW/day in their food. The 
dose of LiCl was 3 mmol/kg BW/day in group 2 and group 3 from 
experimental day 1 to 10 and 4 mmol/kg BW/day from day 11 to 25, 
at which time the study was ended. 
Monitoring of Renal Function 
Total fluid intake was determined every other day by the same 
method that was used in the previous study. 24 hour urine specimens 
were collected on day 15 while the rats had free access to water, 
the NaCl solution and food. Urine flow rate was calculated from 
the volumes of these specimens and expressed as ml/hour/100 g BW. 
A 6 hour urine specimen was collected from 12 MN to 6 AM on day 
16 while the rats had free access to water and the NaCl solution 
but not to food. Urine osmolality was determined on these 6 hour 
specimens and expressed as mOsm/kg H^O. 
The response of the rats to DDAVP was tested by injecting 
DDAVP subcutaneously every 8 hours beginning at 6 AM on day 17 
and ending at 12 MN on day 24. The dose of DDAVP was increased 
from 1500 pg/rat to 15 ng/rat to insure supramaximal doses of 
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DDAVP. On days 18 and 25 a 6 hour urine specimen was collected 
from 12 MN to 6 AM immediately after the 12 MN dose of DDAVP. 
Urine osmolality was determined as described abo«/e. 
Blood and plasma Li concentration was collected in microhematocrit 
tubes from the cut end of the tail vein under light ether anesthesia 
in the morning of days 10 and 25. Plasma Li concentration and 
hematocrit were determined as described above. 
Determination of plasma K concentration was attempted in both 
the Sprague-Dawley and the Brattleboro rats, but was unsuccessful 
because of the difficulty of obtaining nonhemolyzed samples. As 
both Li and amiloride alter K metabolism, plasma K is of special 
interest in this study and should be investigated further. 
3. Statistical Methods 
All statistical data are reported as mean - standard error 
of mean (SEM). Statistical significance was determined using a 
non-paired or, where appropriate, a paired Student's t - test with 
significance set at the 2 P less than .05 level. 
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RESULTS 
Most animals tolerated the experimental procedure well 
and appeared healthy throughout the duration of the study. All 
animal groups gained weight over the course of the experiment 
(Table 1). Two Sprague-Dawley rats and one Brattleboro rac 
in the Li/Ami groups,. and one Sprague-Dawley rat in each of the 
control, Li, Ami, and polyuric control groups developed diar¬ 
rhea and weight loss during the study and were excluded from 
the data analysis. The Brattleboro rats had loose watery 
stools during the equilibration period, probably caused by the 
high osmotic load of the food. This was rapidly corrected by 
the addition of 1 gram Purina Rat Chow to their daily food. 
Because total fluid intake was used to assess the water 
metabolism of these animals, the method of total fluid intake 
measurement was verified as described in the Method section. 
This established that less than 5% of the volume removed from 
full bottles in a 24 hour period was due to leakage or evapo¬ 
ration (Table 2). 
1. Water Metabolism in Sprague-Dawley Rats 
In comparison to controls, chronic Li administration to 
Sprague-Dawley rats significantly increased total fluid intake 
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(Figure 1) and urine flow rate (Figure 2), and significantly 
decreased urine osmolality (Table 3) at all points of measure¬ 
ment after day 6. 
However, the rats that received amiloride in addition to 
Li, in comparison to rats that received Li alone, had signifi¬ 
cantly less total fluid intake (Figure 1), and urine flow rate 
(Figure 2), and significantly increased urine osmolality (Table 
3), at all points of measurement after day 6. During the last 
10 days of the study, the average 24 hour fluid intake of the 
Li/Ami group was 60% less than that of the Li group (28^2 ml/day/ 
lOOg BW vs 69-6, p<.001). Despite this marked improvement in 
urinary concentrating ability, the Li/Ami group, in comparison 
to controls, still had significantly increased total fluid 
intake (Figure 1) and urine flow rate (Figure 2), and signifi¬ 
cantly decreased urine osmolality (Table 3) after day 6. 
The low urine osmolality in the Li group was probably not 
due to low levels of circulatory ADH since administration of 
DDAVP did not increase the urine osmolality of the Li or Li/Ami 
groups significantly by the paired Student's t-test (Figure 3). 
In contrast, DDAVP administration to ADH-deficient Brattleboro 
rats increased their urine osmolality from 220-7 mOsm/kg H^O 
during the baseline collection to 805^127 mOsm/kg H^O (p <0.005 
by paired t). 
■ 
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Plasma Li concentrations were never significantly different 
between the Li and Li/Ami groups (Table 4). Plasma Li con¬ 
centration increased in the Li group from 0.59-.10 mEq/L on 
day 8 to 0.96-.11 (p < .05 by single t) and increased in the 
Li/Ami group from 0.56^.06 to 1.01-.12 (p <.01 by single t). 
There was no evidence that the Li/Ami animals were volume 
contracted in comparison to either controls or Li animals. 
Hemotocrits were not significantly different between animal 
groups on days 43 or 57 (Table 1), and the rate of increase of 
body weight in the Li/Ami group was not significantly different 
from that of the Li group (Table 1). Both the Li and Li/Ami 
groups gained significantly less than controls (Table 1), but 
when food intake was measured daily during week 7, both Li and 
Li/Ami groups ate significantly less than controls (controls 
15.0^.5; Li 12.3-. 2, p <001, Li/Ami 11.6-. 5, p<.001) indicating 
that the difference in average weight gain between groups may 
be due to differences in food intake, and not volume contraction 
Comparable differences in total fluid intake between Li 
and Li/Ami groups were observed in the pilot study. The Li/Ami 
group drank 55% less than the Li group on day 68 (31-3 ml/day/ 
lOOg BW vs 69-12, p < .025). Measurement of C on day 74 
LT0 ciH- 
demonstrated no significant differences between groups (Table 1) 

-38- 
2. Water Metabolism in Brattleboro Rats 
In contrast to the findings in Sprague-Dawley rats, the 
Li/Ami Brattleboro group, in comparison to the Li Brattleboro 
group, had either comparable, or increased total fluid intake 
at all points of measurement (Figure 3), comparable urine flow 
rate (3.92^0.33 ml/h/lOOg BW vs 3.22-0.16 on day 15), and 
comparable urine osmolality (193-22 mOsm/kg H^O vs 164^17) 
(Figure 4 and Table 5). 
Plasma Li concentration was never significantly different 
between Li and Li/Ami Brattleboro groups. On day 10, the P 
of the Li group was 0.67^.08 mEq/L, while the Li/Ami group had 
a P . of 0.63-.02 mEq/L. On day 25, the P . of the Li group was 
L l Ll 
.66^05 mEq/L, while the Li/Ami had a P . of the .63-.03 mEq/L. 
Ll 
At a similar P Li Sprague-Sawley rats had significantly 
increased total fluid intake in comparison to Li/Ami Sprague- 
Dawley rats (50-5 ml/day/lOOg BW vs 25-3 on day 12, p <.005). 
Administration of DDAVP for 8 days significantly reduced 
total fluid intake in both control (p <.001 by paired t) and 
the Li/Ami group (p <.005 by paired t), but not in the Li group 
(Figure 5). Urine osmolality after 8 days of DDAVP administra¬ 
tion was variable and no significant difference in urine 
osmolality between Li and Li/Ami groups could be demonstrated. 
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but there was a trend towards a higher U in the Li/Ami 
osm 
group (Table 5 and Figure 4). 
These data demonstrate that amiloride decreases chronic 
Li induced polyuria in the rat only in the presence of ADH, and 
suggests that amiloride increases the renal tubular response 
to ADH during chronic Li administration. 
3. Sodium Metabolism in Sprague-Dawley and Brattleboro Rats 
Significant differences in NaCl intake were not observed 
between groups on any one day because of variability in intake. 
However, when NaCl intake on several consecutive monitoring days 
were averaged and expressed as mean daily NaCl intake in mmol 
NaCl/day/lOOg BW it could be demonstrated that when both Sprague- 
Dawley and Brattleboro rats were treated with Li/Amiloride 
they drank significantly more NaCl solution than controls, Li, 
or Amiloride animals (Table 1). Significant differences in 
NaCl intake between other groups could not be demonstrated. 
An increased NaCl intake implies that the kidney is 
excreting an increased amount of Na and Cl. Increased excretion 
of Na in animals receiving both Li and amiloride is expected, 
since both are natriuretic agents (8, 47). The obligatory 
water loss from this natriuresis may explain why the Li/Ami 
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Brattleboro rats drank significantly more fluid than either 
the Li, or control Brattleboro animals (Figure 3). 
4. Renal Morphology 
A group of rats rendered polydipsic and polyuric by 
allowing access to a 5% glucose solution were included in the 
morphologic data analysis. In comparison to the Li group, the 
polyuric control group had a comparable mean daily fluid intake 
over the duration of the experiment (49^2 ml/lOOg BW/day vs 
53-3) and comparable urine flow rate (1.61^.26 ml/lOOg BW/h 
vs 2.57^.55 on day 57). These rats appeared healthy, gained 
an equivalent amount of weight as the controls (4.52-.16 g/day 
vs 4.31-.04), and were not glucosuric. 
Light microscopy. Coded renal tissue from the Sprague- 
Dawley rats treated as outlined in Materials and Methods was 
evaluated on two separate occasions by two blinded observers 
and scored on a scale of 0 to 4+ for the presence or absence of 
interstitial inflammation or scarring. 
Lesions of interstitial inflammation were present in all 
groups, but the degree of inflammation was least in the controls 
(o.7^0.2) (Table 6 and Figures 6, 7, 8, 9, 10). However, the 
mean scores in all groups were small (no greater than 2.1-0.6) 
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and no significant difference in scores could be demonstrated 
between the control, Li, and Amiloride groups. Despite the 
low scores in general, two significant differences were 
observed. The Li/Ami group had significantly higher scores 
than controls (2.1-0.6 vs 0.7^0.2, p <.05), but not significantly 
higher than Li treated animals (2.1^0.6 vs 1.2^0.4). Of 
particular interest, the polyuric control group also had a 
. . . . + + 
significantly higher score than controls (2.1-0.4 vs 0.7-0.2, 
p <.01). 
Electron microscopy. In contrast to the findings on light 
microscopy, a striking and previously unreported lesion was 
demonstrated. In the light cells of the cortical collecting 
ducts in all 7 Li treated rats there were bundles of fibrillar 
materials present in the cytoplasm (Table 7 and Figures 11, 12, 
13, 14). This material was not present in the light cells of 
any of the 6 rats not treated with Li (Figures 15, 16, 17). 
This fibrillar material appeared to be aggregations of micro¬ 
filaments. These bundles were not observed in the dark cells 
or in other tubular cells in the cortex. The concurrent 
administration of amiloride appeared to have no protective 
effect. In the single polyuric control animal that was perfused 
adequately for this study, this fibrillar material was not 
present (Figure 17). 
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In addition, in 5 of the 7 rats receiving Li, hypertrophy 
of the collecting duct cells was evident (Figure 12). In 
contrast, only 1 of the 6 rats not receiving Li, an Ami rat, 
had similar cellular hypertrophy (Table 7). 

DISCUSSION 
1. Water Metabolism During Chronic Administration of Li 
And Amiloride In Rats 
An extensive amount of evidence demonstrates that Li 
causes a nephrogenic diabetes insipidus syndrome in humans and 
experimental animals primarily by reducing renal responsiveness 
of ADH at sites both proximal and distal to the generation of 
cAMP (48). The diuretic amiloride has been shown to partially 
reduce the inhibition of free water reabsorption caused by 
acute LiCl infusion in both rats (90) and subhuman primates (151). 
The experiments presented in this thesis demonstrate that, at 
comparable plasma Li concentrations, amiloride reduces by as 
much as 60% the polyuria caused by the chronic administration 
of Li to normal rats with endogenous ADH. 
Pharmacologic agents could reduce the polyuria of diabetes 
insipidus by several different mechanisms. Vasopressin and 
DDAVP, an ADH analog (149), act by substituting for endogenous 
ADH when there is partial or complete deficiency of this 
hormone (81). Although vasopressin and ADH analogs are effective 
in hereditary or acquired pituatary diabetes insipidus, they 
have little or no effect in idiopathic or drug induced nephro¬ 
genic diabetes insipidus (81). 
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Thiazide diuretics produce an antidiuresis by causing 
natriuresis and modest extracellular volume contraction. The 
subsequent reduction of glomerular filtration rate and increase 
in proximal tubular reabsorption of filtrate decreases the 
delivery of filtrate to the distal nephron and reduces the 
generation and loss of free water (41, 108). This antidiuresis 
will persist when the drug is stopped if sodium restriction and 
modest volume contraction are maintained. The antidiuretic 
effect of thiazides is ADH independant since it occurs whether 
ADH is present or not. The polyuria of both central and 
nephrogenic diabetes can be reduced by thiazides, but electro¬ 
lyte disturbances (hypokalemia, metabolic alkalosis) and changes 
in the excretion of other substances reabsorbed in the proximal 
tubule (lithium, uric acid, calcium) may be encountered (81, 97, 
138) . 
The antidiuretic effect of the oral hypoglycemic agent 
chlorpropamide is due to both enhanced ADH release (95) and 
potentiation of the renal action of ADH by impairing PGE2 
production (16, 92, 95, 154). Chlorpropamide s mechanism of 
action is ADH dependant since ADH must be present to cause an 
enhanced antidiuresis. Chlorpropamide does not increase water 
flow in toad urinary bladders in the absence of ADH (154) and 
does not reduce the polyuria in ADH deficient Brattleboro 
' -' 
, 
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rats (16). It is an effective agent only in patients with 
partial central diabetes insipidus and is specifically ineffective 
in chronic Li-induced polyuria (25, 45, 81). 
There have been attempts to reverse drug induced nephro¬ 
genic diabetes insipidus by using agents that may act at sites 
distal to where the cellular action of ADH is blocked. However, 
in Li induced diabetes insipidus in rats,, infusions of cAMP 
analogs, dibutryrl cAMP (45, 89) or ClPhe S-cAMP (28), either 
had no effect or a blunted effect on the Li-induced polyuria. 
Obviously, even if the cAMP analogs presently available 
completely reversed the polyuria, infusions of such substances 
would be impractical for therapy. 
Amiloride could decrease Li induced polyuria by 1) causing 
natriuresis and volume contraction and a subsequent fall in 
the delivery of filtrate to the distal tubule, 2) increasing ADH 
release, or 3) increasing the renal tubular response to ADH. 
The present experiments suggest that volume contraction per 
se is not the mechanism for the antidiuretic effect of amiloride 
in chronic Li polyuria. First, the experimental method avoided 
volume contraction by allowing access to a NaCl solution. 
Hematocrit, body weight, and creatinine clearance were not 
different between Li and Li/Amiloride rats. Second, if amiloride 
acted by producing volume contraction - an ADH independent 
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mechanism - it should have reduced the polyuria in ADH-deficient 
Brattleboro rats. Yet, the Li/Ami Brattleboro group, in 
comparison to the Li Brattleboro group, had comparable or 
increased total fluid intake, comparable urine flow rate, and 
comparable urine osmolality. 
One objection to this argument is that this experiment 
compares the effects of Li and amiloride in two different 
species of rat. Brattleboro rats may differ from Sprague- 
Dawley rats in other ways than ADH deficiency. However, other 
agents, e.g., thiazides, that cause a natriuresis and mild 
volume contraction will reduce the polyuria of Brattleboro 
rats (138). Therefore, the administration of Li and amiloride 
to Brattleboro rats should reduce the polyuria if amiloride 
causes volume contraction under the experimental conditions of 
this study. 
The major inconsistency in the data is the failure to 
produce significant differences in urine osmolality between 
the Li and Li/Ami Brattleboro groups by administering DDAVP. 
An increased responsiveness of the Li/Ami group to DDAVP was 
expected. The Li/Ami and the control groups, but not the Li 
group, significantly reduced their fluid intake after DDAVP 
administration. However, the total fluid intake and the urine 
osmolality of the Li/Ami group was not significantly different 
. 
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from the Li group. However, significant differences in urine 
osmolality may have been demonstrated had there been a larger 
number of animals. In addition, the pharmacological repletion 
of a normally endogenous hormone is an imperfect substitute 
for the presence of a normal neurohypophysis that is capable 
of secreting physiologic amounts of ADH. 
Other studies suggest that amiloride causes an antidiuresis 
in Li-treated Sprague-Dawley rats by reversing the effect of Li 
to inhibit the renal tubular responsiveness to ADH, and not 
by enhancing ADH release. First, the administration of vaso¬ 
pressin to Li treated animals and humans does not improve the 
Li-induced urinary concentrating defect (45, 119, 61). Enhanced 
endogenous secretion of ADH would then not be expected to cause 
an antidiuresis. Second, there is direct evidence that amiloride 
reverses the effect of Li to inhibit cellular response to ADH. 
Singer and Franko demonstrated in toad urinary bladders that 
-5 
amiloride (10 M) on the mucosal side blocked the effect of 
mucosal Li (11 mEq/L) on ADH mediated water flow (120) . 
Lithium is transported across the mucosal membrane of 
amphibian epithelial cells through a Na channel (111) . Because 
amiloride has been demonstrated to block this Na channel, 
amiloride may reverse Li induced polyuria by reducing cellular 
entry of Li. In support of this hypothesis is the demonstration 

-48- 
by Herrara et al that mucosal amiloride reduced tissue Li 
content on Li-treated toad urinary bladders (66). This hypo¬ 
thesis is compatible with evidence that distal reabsorption 
of Li is quantitatively unimportant. For detectable Li re¬ 
absorption to occur there must be significant transport of Li 
out of the cell across the serosal membrane. The hypothesis 
does assume that intracellular, not extracellular, Li is 
responsible for the alteration in cellular responsiveness to 
ADH. The evidence that supports an intracellular site of 
action is the demonstration that Li inhibits dibutryrl cAMP 
stimulated antidiuresis (47, 89), and that Li inhibits ADH 
stimulated assembly of microtubules in renal medullary tissue (39). 
An additional assumption is that Li enters the collecting duct 
cell primarily from the luminal side. However, as discussed in 
the Introduction, experiments in toad urinary bladders yield 
contradictory evidence regarding the side of the membrane from 
which Li acts (15, 61, 119, 120). 
An alternative explanation for the antidiuretic effect of 
amiloride during Li administration could be amiloride's potent 
inhibition of potassium secretion. Li accumulates intracellularlv 
at the expense of Na and potassium in muscle (22), nerve cells (150) 
bladder epithelium (66), and renal tissue (61). This loss of 
the usual intracellular cations may alter cellular function. In 
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another disorder, severe hypokalemia is associated with both 
a defect in urinary concentration and morphologic lesions in 
the kidney (125). Amiloride could reverse Li induced polyuria 
by preventing the loss of intracellular potassium. In Li 
treated toad urinary bladders, amiloride significantly increased 
tissue potassium content, in addition to reducing tissue Li 
content (66). The present studies do not exclude the possibility 
that the antidiuretic effect of amiloride may involve main¬ 
tenance of the normal intracellular potassium concentration. 
The present observations may have specific application 
to lithium induced polyuria in man. In 10% of patients receiving 
Li, a profound polyuria occurs that is not only inconvenient 
for the patient, but potentially dangerous (45, 145, 146) . 
Should the patient be unable to replace urinary water loss, 
volume contraction and Li intoxication may result (146). Thiazide 
diuretics have been used successfully to reduce the polyuria, 
but they act by causing volume contraction and predispose the 
patients to Li intoxication (69, 88). 
The present studies demonstrate that amiloride specifically 
inhibits lithium's effect on urinary concentration in rats by 
a mechanism that does not involve significant volume contrac¬ 
tion or increase in plasma Li concentration when adequate dietary 
NaCl is available. Therefore, amiloride may be superior to 
thiazides in the therapy of Li-induced polyuria. It is 
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important to consider that amiloride could also specifically 
block the therapeutic effect of Li on the central nervous 
system. However, since diuretics are actively secreted by 
the organic acid and base pathways in the proximal tubule (81), 
effective concentrations of amiloride may only be attained in 
the renal tubule. The present studies support the establish¬ 
ment of clinical trials to investigate the effect of amiloride, 
in comparison with thiazides, in patients with chronic Li- 
induced polyuria. 
2. Renal Morphology after Chronic Administration of Li and 
Amiloride to Sprague-Dawley Rats 
In this study, marked differences in the degree of 
interstitial inflammation between groups (Controls, Li, Li/Ami, 
Ami and polyuric controls) could not be demonstrated by 
quantitative means on light microscopy in rats after eight 
weeks of drug administration (Table ). Areas of cellular 
infiltration were focal, small in size, and few in number. 
However, in one animal, a Li/Ami rat, both widespread infiltra¬ 
tion of the cortex and interstitial fibrosis was present. 
These results are in contrast to Hestbech et al who, under 
almost identical experimental conditions, detected early 
changes of focal cortical inflammation in nine of twelve Li 
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treated anima.1 after nine weeks, but in none of the six 
controls (68). One explanation for these conflicting results 
is that plasma Li concentrations were higher in their rats in 
comparison to ours (1.1-0.2 mEq/L to 1.3^0.3 vs 0.6-0.1 to 
1.0^0.1), although both studies maintained Li levels within 
the therapeutic range. Also, Hestbech et al used male Wistar 
rats, in comparison to our use of male Sprague-Dawley rats. 
Birch has reported that male Sprague-Dawley rats develop 
spontaneous changes that can be indistinguishable from those 
reported with Li (18). Control rats in our study did have 
lesions comparable to those in Li-treated rats and consistant 
with the lesions described by Hestbech. Although the degree 
of interstitial inflammation was lowest in the controls, even 
this rate of spontaneous change could obscure differences 
between groups. 
Despite the relatively mild lesions observed, two important 
findings were demonstrated by light microscopy. First, by semi- 
quantitative measurement, the Li/Ami group had significantly 
greater lesions than controls (p <.05), though not significantly 
greater than rats treated with either Li or amiloride alone. 
It is possible that a drug interaction from the two agents may 
contribute to increased interstitial inflammation. However, 
the absence of any significant difference in scores between the 
Li and Li/Ami rats suggests that this effect is minimal. 
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Second, it was of particular interest that the polyuric 
control group, with a comparable polyuria as the Li rats, had 
significantly greater interstitial fibrosis than controls. To 
our knowledge, there have been no previous reports of renal 
morphologic damage associated with primary polydipsia. This 
observation suggests that Li associated morphologic changes 
may be due to polyuria per se. Future studies of Li induced 
renal damage in experimental animals should include polydipsic 
animals as a means to control for morphologic damage caused by 
polyuria alone. 
In contrast to the limited findings by light microscopy, 
marked differences between groups were observed by electron 
microscopy. In all seven rats that received Li, but in none 
of the six rats not receiving Li, distinct bundles of cyto¬ 
plasmic fibrils were observed in the light cells of the collect¬ 
ing ducts. They were not observed in dark cells of the collect¬ 
ing duct, or in portions of the distal tubule or proximal 
tubule observed in the sections. 
These structures have not been described previously in 
chronic Li-treated experimental animals or humans. Evan and 
Ollerich (44) described renal ultrastructural changes after Li 
administration to rats, but they did not observe these fibrillar 
bundles. However, the study differed from ours in that a 
different fixative solution was used (gluteraldehyde vs 
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glut er aldehyde and paraformaldehyde), the method of vascular 
perfusion was different (left ventricular vs aortic retrograde), 
and the administration of Li was parenteral instead of oral. 
Practically identical bundles of cytoplasmic fibrils have 
been reported in various types of cultured cells (19, 54), 
and in toad urinary bladder epithelium (132). The presence of 
a complex array of cytoplasmic fibrils was first described in 
fixed cells in 1899(64), and living cells in 1924 (86). With 
the advent of the electron microscope, interest in cytoplasmic 
fibrils increased as it became apparent that these structures 
were actively involved in cell movement (54). 
Fibrils are present in two forms in cultured cells: 1) 
meshworks of loosely organized fibrillar arrays, and 2) bundles 
of fibrillar material, initially called stress fibers, that 
are identical in appearance to the bundles observed in Li- 
treated animals (19, 54). Light and electron microscopy of 
cultured cells demonstrate that these stress fibers consist 
of 5 to 7.5 microfilaments (19). Their presence in living 
cells is evidence that these structures are not fixation 
artifacts. To preserve these fibrils fixatives must permeate 
the cell quickly in order to prevent depolymerization. The 
combination of gluteraldehyde with paraformaldehyde, a low 
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molecular weight fixative that diffuses rapidly across cell 
membranes, would be superior to gluteraldehyde alone. We 
believe that this difference in fixation technique may explain 
why Evan and Ollerich failed to demonstrate these bundles in 
Li-treated rats. 
Li-induced alterations in cellular function may be related 
to the formation of these bundles in Li-treated animals. Buckley 
and Porter observed that in cultured cells microfilament bundles 
were static even in the presence of actively undulating move¬ 
ments of the cell membrane (19). They speculated that the 
microfilaments closely associated in bundles were in some way 
partially inactivated. By causing aggregation of microfilaments 
into bundles, Li may disrupt the normal organization of cyto¬ 
plasmic fibrils and disturb cellular function dependant on the 
presence of a loose array of microfilaments. 
It has recently been proposed that microfilaments may 
play a role in the intracellular events that cause ADH mediated 
increases in water permeability (38). Cytochalasin B, a 
macrolide antibiotic that disorganizes microfilament structure, 
reversibly inhibits both ADH and cAMP mediated water flow in 
the toad bladder (32, 33, 132). One proposed mechanism is that 
microfilaments, in the presence of ADH, alter the lateral 
plasma membrane in such a way as to increase the passive flow 
. 
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of solutes and water across this barrier (38). Large intra¬ 
cellular vacuoles, observed in the toad urinary bladders treated 
with ADH and cytochalosin B, may reflect an inability of water 
to cross the lateral plasma membrane (32). An alternative 
hypothesis is that microfilaments are involved in a micro¬ 
tubular mediated increase in water permeability (38). Bio¬ 
chemical evidence demonstrates that microfilaments and micro¬ 
tubules interact with each other in in vitro systems (54). 
Dousa et al have demonstrated that Li inhibits ADH stimulated 
microtubular assembly in renal medullary tissue (39). These 
data suggest a link between Li induced diabetes insipidus and 
microfilament bundles observed in rats treated with Li. 
One limitation with this line of reasoning is the 
observation that, although amiloride significantly reduces the 
Li induced polyuria, probably by increasing cellular response 
to ADH, it did not prevent the formation of microfilament 
bundles in the Li/Ami group. In addition, the presence of 
these bundles in the Li/Ami group implies that amiloride does 
not completely block the entry of Li into the cell. This would 
suggest that either 1) amiloride may act to increase cellular 
responsiveness to ADH by a mechanism other than preventing 
Li entry, or 2) microfilament bundles may be a marker of the 
presence of Li, but not involved in li-induced nephrogenic 
■ 
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diabetes insipidus. However, since analysis was limited to 
qualitative assessment, and not quantitative measurement of 
the number of microfilament bundles in each specimen, a 
quantitative comparison of microfilament bundles between Li 
and Li/Ami groups cannot be made. 
Renal cell hypertrophy was also observed in five of seven 
Li treated animals, but in only one of six rats who did not 
receive Li (Table 4). Apparent cell hypertrophy can result 
from fixation artifacts or sectioning. However, some of the 
cells in the collecting duct were strikingly enlarged (Figure 
14 ) and appeared to have some rarefaction of the apical 
cytoplasm. Cellular hypertrophy of cells in the distal nephrons 
is described by Evan and Ollerich in their ultrastructural 
study, and by several light microscopy studies of patients (20) 
or experimental animals (67). 
Because we elected to concentrate on changes in cortical 
collecting ducts, we could not determine if the specific 
ultrastructural lesions of hypokalemic nephropathy were present. 
The multivesicular cytoplasmic bodies characteristic of this 
disorder occurs only in medullary and papillary cells (125); but 
for technical reasons, these areas were not examined. 
Further investigation of Li-induced morphologic changes 
should establish 1) if these microfilament bundles are present 
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in the medulla or papilla, 2) whether the appearance of these 
bundles is temporally related to the onset of reduced renal 
tubular responsiveness to ADH, 3) if this lesion is reversible 
upon discontinuation of Li. In addition, since the effects 
of Li on the kidney may be related to intracellular loss of 
potassium, ultrastructural analysis of medullary and papillary 
collecting ducts for the characteristic lesions of hypokalemic 
nephropathy is important. If they were present, it would be 
interesting to see what effect amiloride has on these lesions. 
Finally, the absence of these bundles in the single polyuric 
rat studies by electron microscopy does not sufficiently exclude 
the possibility that high plasma ADH levels are responsible for 
the presence of these bundles in Li-treated rats. Further 
ultrastructural analysis of cortical collecting ducts from 
polyuric control rats must be done. 
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TABLE la. Intake of NaCl solution in Brattleboro rats. 
Groupa n Intake of NaCl solution13 
(mmol NaCI/day/lOOg BW) 
Control 5 1.4 ± 0.2 
Li 5 1.3 ± 0.1 
Li/Ami 4 2.8 ± 0.1 *,+ 
a Animal groups were Control, lithium treated (Li), lithium and ami- 
loride treated (Li/Ami) Brattleboro rats. Comparison of values be¬ 
tween groups tested for significance by unpaired Student's t - test. 
All values are means ± SEN!. 
b The intake of a 0.46 M NaCl solution during the duration of the 
study were averaged and expressed as mean daily NaCl intake in mmol/ 
day/lOOg BW. 
* p <.001 vs. Control 
+ p <.001 vs. Li 

TABLE 2. Water loss from evaporation and leakage during measurement of total 
fluid intake. 
Volume removed (ml)a_Water loss in 24 hours% Error13 
0 1.0 + 0.5 
59.3 + 0.7 1.5 + 0.7 2.5 
120.7 + 0.9 1.7 + 0.4 1.4 
179.0 ± 0.7 5.2 + 0.9 2.9 
305.8 + 3.1 10.5 + 1.2 3.4 
a At time 0, these recorded volumes were removed with a polyethylene catheter 
from bottles in position on a metabolic rack (n=6 for each volume). Water 
loss was determined gravimetrically 24 hours later. 
b The % Error here is an expression of the fraction of fluid removed from the 
bottles by evaporation and leakage, and not by fluid intake by the animals. 
It is defined as: Water loss in 24 hours X 100. 
Volume removed 

TABLE 3. Urine osmolality in Sprague - Dawley rats. 
Group3 n Baseline urine osmolality (Un Un after DDAVPC 
Day 35_Day 51 usm usm 
Control 6 1256 + 243 1280 + 122 1728 ± 295 
Ami 5 1105 + 151 1179 + 166 1354 + 169 
Li 5 269 + 105 *,# 229 + 42 *,# 318 ± 88 *,# 
Li/Ami 6 842 ± 96 + 546 + 58 *,+,# 626 + 38 *,+,# 
a Animal groups were Control, lithium treated (Li), amiloride treated 
(Ami), and lithium and amiloride treated (Li/Ami) male Sprague - 
Dawley rats. Comparison of values between groups tested for sign- 
ficance by unpaired Student's t - test. All values are means ± SEM. 
b Osmolality determined on urine collected from 12 MN to 6AM on days 
35 and 51. Rats had access to water and the 0.46 M NaCl solution, 
but not to food. Values expressed as mOsm/kg HgO. 
c Osmolality determined on urine collected from 12 MN to 6 AM on day 
52 after rats had received DDAVP 1500 pg/rat subcutaneously at 6 AM, 
12 N, 6 PM, and 12 MN on the day before the urine collection. The 
rats had access to water and the NaCl solution, but not to food. By 
paired Student's t - test, there was no significant increase in Ugsm 
from baseline on day 51 after administration of DDAVP in any of 
the groups. Values expressed as mOsm/kg H^O. 
* p <.05 or below vs. Controls 
+ p <.05 or below vs. Li 
# p <.05 or below vs. Ami 

TABLE 4. Plasma lithium concentration9 in lithium or lithium and amiloride 
treated Sprague-Dawley rats. 
Experimental day^U 
8 
16 
29 
43 
57 
ium treated rats (mEq/L)c 
0.59 ± 0.10 
0.71 ± 0.13 
0.98 ± 0.11 
0.92 ± 0.11 
0.96 ± 0.11 
Li/amiloride rats (mEq/L)^ 
0.56 ± 0.06 
0.74 ± 0.07 
0.71 ± 0.08 
0.92 ± 0.14 
1.01 ± 0.12 
a Blood obtained in the morning from the cut end of the tail vein of rats under light 
ether anesthesia. Plasma Li concentration determined on a Perkin-Elmer atomic 
absorption spectrophotometer. 
b Plasma Li concentration in Li and Li/amiloride treated rats compared by single 
Student's t-test, p>.05 for each experimental day. 
c n=5 
d n=6 

TABLE 5. Urine osmolality in Brattleboro rats. 
Group9 n Baseline urine osmolality (Un )b Un after DDAVPC Statistics'^ 
(mOsm/kg H^O)usymOsm/kg HpO) 
Control 5 220 + 7 1199 + 58 P <.001 
Li 5 164 ± 17 501 + 104** P <.01 
Li/Ami 4 193 + 22 758 + 113* P <.02 
a Animal groups were Control, lithium treated (Li), and lithium and ami- 
loride treated (Li/Ami) male Brattleboro rats. Comparison of values 
between groups were tested for significance by Student's t - test. 
All values are expressed as mOsm/kg H^O, and are means ± SEM. 
b Osmolality determined on urine collected from 12 MN to 6 AM on day 17. 
Rats had access to water and a 0.46 M NaCl solution, but not to food. 
c Osmolality determined on urine collected from 12 MN to 6 AM on day 25 
after rats had received DDAVP every eight hours for eight days. The 
dose of the DDAVP was increased from 1500 pg/rat to 3000 pg/rat on 
day 21, and then to 6000 pg/rat. This dose was given subcutaneously. 
During the collection, the rats had access to water and the NaCl sol¬ 
ution, but not to food. 
* p <.01 vs. Control 
** p <.001 vs. Control 

TABLE 6. Semiquantitative analysis of the severity of interstitial inflammation 
by light microscopy. 
Animal group n Mean score' 
Control 6 0.7 ± 0.3 
Lithium treated 5 1.2 ± 0.4 
Amiloride treated 5 1.5 ± 0.5 
Li/amiloride treated 6 2.1 ± 0.6 
Polyuric control0 5 2.1 ± 0.4 
a Each rat had one section of their kidney coded and then scored by two observers 
on a scale of 0 - 4+ for the severity of interstitial infiltrates and scarring. 
This was done on two separate occasions and the scores of the two observations 
were averaged for each rat. See text for details of the scale. 
b Sprague-Dawley rats on a normal diet were rendered polydipsic and polyuric by 
allowing free access to a 5% glucose solution. 
* Significantly greater than controls (p<.05) 
** Significantly greater than controls (p<.01) 

TABLE 7. Qualitative analysis of ultrastructurea by electron microscopy. 
Animal b Microfilament bundles0 
C4 
C5 
C6 
Li 4 
Li 5 
Li 6 
+ 
+ 
+ 
Ami 
Ami 
Ami 
Li/Ami + 
Li/Ami + 
Li/Ami + 
Li/Ami + 
PC4 
Cellular hypertrophy d 
+ 
+ 
+ 
+ 
+ 
+ 
a Coded photomicrographs were viewed by two observers independent of each other. 
There was complete agreement between the two observers on the presence or absence 
of the two lesions (microfilament bundles or cellular hypertrophy) in each rat. 
b Animal groups were control (C), lithium treated (Li), lithium and amiloride treated 
(Li/Ami), amiloride treated (Ami), and normal rats that were rendered polydipsic 
and polyuric by allowing them free access to a glucose solution (PC). In this 
latter group, only one animal was adequately perfused for analysis. 
c Prominent aggregates of fibrillar material in the cytoplasm of the light cells of 
the collecting duct. ( + = present, - = absent). 
d Marked increase in cell size in comparison to both controls and other cells present 
in the section, and apical rarefaction ( + = present, - = absent). 

*p <0.05 or below Li vs Control 
+ p <0.05 or below Li vs Li/Ami 
*p<0.05 or below Li/Ami vs Control 
FIGURE 1. Total fluid intake in control, lithium treated (Li), and lithium 
and amiloride treated (Li/Ami) Sprague - Dawley rats. This represents the 
sum of the intake of water and a 0.46 M NaCl solution during a 24 hour 
monitoring period. Values are expressed as ml/day/lOOg BW, and are means 
± SEM. Comparison of values between groups was tested for significance 
by unpaired Student's t - test. 

GROUP 
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< £ 
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_l o 
Z> 
2.2 
1.4 
0.6 
0 
Control vs Li 
Control vs Li/Ami 
Li/Ami vs Li 
p<0.005 
p <0.001 
p<0.02 
FIGURE 2. Urine flow rate during a 24 hour urine collection on day 57 in 
control, lithium treated (Li), and lithium and amiloride treated (Li/Ami) 
Sprague - Dawley rats. Values are expressed as ml/hour/lOOg BW, and are 
means ± SEM. Comparison of values between groups was tested for signifi¬ 
cance by unpaired Student's t - test. 

FIGURE 3. Total fluid intake in ocntrol, lithium treated (Li), and lithium 
and amiloride treated (Li/Ami) Brattleboro rats. This represents the sum 
of the intake of water and a 0.46 M NaCl solution during a 24 hour monitoring 
period. Values are expressed as ml/day/lOOg BW, and are means ± SEM. Com¬ 
parisons of values between groups was tested for significance by unpaired 
Student's t - test. 

FIGURE 4. Urine osmolality in control, lithium treated (Li), and lithium 
and amiloride treated (Li/Ami) Brattleboro rats. Baseline represents the 
osmolality of urine collected from 12 MN to 6 AM on day 16. DDAVP repre¬ 
sents the osmolality of urine collected from 12 MN to 6 AM after 8 days of 
administering DDAVP every eight hours subcutaneously. The dose of DDAVP 
was increased from 1500 pg/rat to 3000 pg/rat on day 4 of DDAVP admini¬ 
stration, and to 6000 pg/rat on day 6 of DDAVP administration. Values 
are expressed as mOsm/kg LL0, and are means ± SEM. Comparison of values 
between groups was tested for significance by unpaired Student's t - test. 
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FIGURE 5. The reduction in total fluid intake in control, lithium treated 
(Li), and lithium and amiloride treated (Li/Ami) Brattleboro rats after 
administration of DDAVP every 8 hours for eight days. The dose of DDAVP 
was increased from 1500 pg/rat to 3000 pg/rat on day 4, and to 6000 pg/rat 
on day 6, and was given subcutaneously. The total fluid intake of each 
group on day 15 before the administration of DDAVP was arbitrarily set at 
100%. Total fluid intake on succeeding days of the study during DDAVP 
administration was expressed as the percent of the total fluid intake on 
day 15. Values are means ± SEM. Each value was compared within the group 
to the baseline total fluid intake by paired Student's t - test. At no 
point of measurement was there a significant difference in total fluid 
intake between the Li and Li/Ami groups by unpaired Student's t - test. 

FIGURE 6. Light micrograph of the cortex of a Sprague - Dawley rat 
on a control diet for 58 days. This section has no evidence of cell¬ 
ular infiltrate or fibrosis. This animal was given a score of 0 on a 
scale of 0 to 4+ for evidence of interstitial inflammation. Magni¬ 
fication 40X. 

FIGURE 7. Light micrograph of the cortex of a lithium treated Sprague 
Dawley rat. This section demonstrates a focal area of interstitial in 
flanimation. The glomeruli appear normal by light microscopy. This 
animal was given a score of 2.5+ on a scale of 0 to 4+ for evidence 
of interstitial inflammation. Magnification 40X. 
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FIGURE 8. Light micrograph of the cortex of an amiloride treated Sprague - 
Dawley rat. This section includes a vessel and a large area of tissue dis¬ 
ruption that may be an artifact of fixation. However, there are several 
areas of focal infiltration around this disruption (arrows). Glomeruli 
appear normal. This animal was given a score of 3+ because of the presence 
of other areas of infiltration in the cortex. Magnification 40X. 

FIGURE 9. Light micrograph of the cortex of a lithium and amiloride 
treated Sprague - Dawley rat. Section demonstrates marked fibrosis 
and infiltration. Glomeruli within areas of fibrosis appear sclerotic 
but outside of the lesions the glomeruli appear normal. This animal 
was the only animal that had significant fibrosis, and was given a 
score of 4+. Magnification 40X. 
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FIGURE 10. Light micrograph of the cortex of a Sprague - Dawley rat 
that had been rendered polydipsic and polyuric by allowing free access 
to a 5% glucose solution. These polyuric control animals appeared 
healthy, gained weight, and were not glucosuric. The section demon¬ 
strates an area of focal infiltration within the parenchyma that is 
indistinguishable from that seen in the kidneys of the lithium treated 
animals. This animal was given a score of 3+. Magnification 40X. 

FIGURE 11. Electron micrograph of a light cell from the cortical 
collecting duct of a lithium treated Sprague - Dawley rat. Aggregates 
of fibrillar material (arrow) are present in the cytoplasm towards 
the center of the cell. Magnification 6,250X. 

o 
FIGURE 12. Electron micrograph of a light cell from the cortical col¬ 
lecting duct of a lithium treated Sprague - Dawley rat. This cell is 
hypertrophied and has apical rarefaction. Small bundles of.fibrillar 
material are visible in the perinuclear region. Magnification 10,000X. 

FIGURE 13. Electron micrograph of a light cell from the cortical col¬ 
lecting duct of a lithium and amiloride treated Sprague - Dawley rat. 
Aggregates of fibrillar material can be seen in the cytoplasm (arrow). 
The separation of the cell from the basement membrane is probably an 
artifact of fixation. Magnification 10,000X. 
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FIGURE 14. Electron micrograph of a light cell from the cortical col¬ 
lecting duct of a lithium and amiloride treated Sprague - Dawley rat. 
This micrograph demonstrates both cellular hypertrophy and apical rare¬ 
faction, and distinct fibrillar bundles in the cytoplasm. Magnification 
1Q,00QX. 

FIGURE 15. Electron micrograph of a light cell and a portion of a dark 
cell of a cortical collecting duct from a control Sprague - Dawley rat. 
There is no fibrillar material and no cellular hypertrophy. Magnifi¬ 
cation 10,000X. 

FIGURE 16. Electron micrograph of a light cell from the cortical col¬ 
lecting duct of an amiloride treated animal. There are no abnormalities. 
Magnification 6,250X. 

FIGURE 17. Electron micrograph of a light cell and a portion of a dark 
cell from the cortical collecting duct of a polyuric control Sprague - 
Dawley rat that had free access to a 5% glucose solution. The cells 
are not hypertrophied, and there is no fibrillar material in the 
cytoplasm of either cell. Magnification 10,000X 
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